Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Immunomodulatory effects of sustained pantethine release in inflammatory diseases

Objective

Auto-immune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA) and inflammation-associated brain diseases including Alzheimer's disease (AD) globally make up a €45B market and cost society close to €648B. The huge number of patients with these diseases causes an enormous socioeconomic burden. Currently, MS, AD and RA affect 120M people worldwide. There is no cure for AD and treatments for autoimmune diseases are not fully effective and reducing the inflammatory component in these diseases is a key strategy.
As a result of our ERC StG NEUROTRAFFICKING we found that a natural molecule, which is Coenzyme A precursor (CoAP), modulates leukocyte trafficking and has anti-inflammatory properties that are, however, limited in effectiveness due to fast breakdown in the gut. Our preliminary data demonstrate that derivatives of CoAP hydrolysis are devoid of antiinflammatory effects and that intact CoAP is required for its therapeutic effect in mouse models of MS and AD. The goal of IMPEDE is to develop a proprietary formulation of CoAP that protects it from hydrolysis and its disulphide bonds from degradation. This provides a novel and highly promising therapeutic approach for the inflammatory diseases, either for combination or stand-alone treatment. A patent application for this novel CoAP formulation has been filed. Subsequent steps will be taken in IMPEDE to generate and validate a more effective product through improved formulation and to prepare further regulatory and IP strategies, design a business strategy
and perform market research. Overall, IMPEDE offers a rapid valorisation of the ERC StG grant on one hand and of the novel CoAP formulation on the other hand. It will generate a novel CoAP formulation with high therapeutic potential in autoimmune diseases and other inflammatory diseases.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

ERC-POC - Proof of Concept Grant

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) ERC-2015-PoC

See all projects funded under this call

Host institution

UNIVERSITA DEGLI STUDI DI VERONA
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 150 000,00
Address
VIA DELL ARTIGLIERE 8
37129 Verona
Italy

See on map

Region
Nord-Est Veneto Verona
Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 150 000,00

Beneficiaries (1)

My booklet 0 0